Unknown

Dataset Information

0

Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.


ABSTRACT: BACKGROUND:It remains unclear whether patients' self-perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first-line cetuximab and standard chemotherapy. METHODS:The data were collected from a prospective trial that assessed the relationships between quality of life (QOL), treatment efficacy, and adverse events (AEs). RESULTS:The analysis of 137 mCRC patients revealed a significant association between the presence of baseline tumor-related symptoms and a lower overall survival (OS) compared to the absence of symptoms (HR, 2.49; 95% CI, 1.37-4.62; P = .003). The asymptomatic responders had favorable outcomes compared to the symptomatic nonresponders (2-year OS rates: 83.6% and 35.9%, respectively), while the symptomatic responders had similar outcomes to the asymptomatic nonresponders. The median postprogression survival differed significantly: 10.2 months for the symptomatic patients and 15.9 months for the asymptomatic patients (HR, 2.29; 95% CI, 1.25-4.29, P = .008). The objective response rates and patient toxicity profiles were similar irrespective of the severity of baseline symptoms. CONCLUSION:Baseline symptoms were associated with worse OS but not with impaired treatment efficacy or more frequent AEs in mCRC patients treated with cetuximab in addition to chemotherapy.

SUBMITTER: Ooki A 

PROVIDER: S-EPMC7050093 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.

Ooki Akira A   Morita Satoshi S   Iwamoto Shigeyoshi S   Hara Hiroki H   Tanioka Hiroaki H   Satake Hironaga H   Kataoka Masato M   Kotaka Masahito M   Kagawa Yoshinori Y   Nakamura Masato M   Shingai Tatsushi T   Ishikawa Masashi M   Miyake Yasuhiro Y   Suto Takeshi T   Hashiguchi Yojiro Y   Yabuno Taichi T   Sakamoto Junichi J   Tsuji Akihito A   Ando Masahiko M   Yamaguchi Kensei K  

Cancer medicine 20200121 5


<h4>Background</h4>It remains unclear whether patients' self-perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first-line cetuximab and standard chemotherapy.<h4>Methods</h4>The data were collected from a prospective trial that assessed the relationships between quality of life (QOL), treatment efficacy, and adverse events (AEs).<h4>Results</h4>The analysis of 1  ...[more]

Similar Datasets

| S-EPMC7774728 | biostudies-literature
| S-EPMC9238042 | biostudies-literature
| S-EPMC6144158 | biostudies-literature
| S-EPMC4905480 | biostudies-literature
| S-EPMC8124114 | biostudies-literature
| S-EPMC5181797 | biostudies-other
| S-EPMC6291650 | biostudies-literature
| S-EPMC8664812 | biostudies-literature
| S-EPMC9563947 | biostudies-literature
| 2437688 | ecrin-mdr-crc